4 stories mentioning SHA:600521Updated 15d ago
Every FINWIRES story that references SHA:600521, newest first.
China's drug regulator approved Zhejiang Huahai Pharmaceutical's (SHA:600521) iguratimod tablets for rheumatoid arthritis, according to a Tuesday filing with the Shanghai bourse.
Zhejiang Huahai Pharmaceutical (SHA:600521) obtained registration for two drugs from China's medical products administrator.Brexpiprazole tablets are indicated for adult schizophrenia and isavuconazonium sulfate injection for invasive aspergillosis and mucormycosis, according to a weekend filing with the Shanghai bourse.Shares of the drugmaker closed 1% higher Monday.
Zhejiang Huahai Pharmaceutical's (SHA:600521) attributable profit slid 76% to 266.9 million yuan in 2025 from 1.12 billion yuan in 2024, according to a Wednesday filing with the Shanghai bourse.Earnings per share at the drug manufacturer decreased 77% to 0.18 yuan from 0.77 yuan in the previous year.Operating income declined 10% year over year to 8.59 billion yuan from 9.55 billion yuan.Shares increased 2% during morning trading on Wednesday.
Zhejiang Huahai Pharmaceutical (SHA:600521) forecasts its attributable profit will rise 30% to 48% to between 387 million yuan and 440 million yuan in the first quarter from 297.4 million yuan in the year-ago period, according to a Wednesday filing with the Shanghai bourse.The expected rise is attributable to gains from the offloading of a 67% stake in subsidiary Huahai Tianheng (Shanghai) Pharmaceutical Research, the filing said.Shares rose 2% during morning trading on Wednesday.
